FIBATIDE 2mg|ml Injection 10ml vial

Frequently asked questions

• Onset of action

  The effect of this medicine can be observed immediately following an intravenous administration.

• Duration of Effect

  The effect of this medicine lasts for an average duration of 4 to 6 hours.

• Safe with Alchohol?

  Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.

• Is it habit forming?

  No habit-forming tendencies were reported.

• Usage in pregnancy?

  This medicine is not recommended for use in pregnant women unless absolutely necessary. Your doctor will determine the best course of treatment after evaluating the potential benefits and risks associated with the use of this medicine.

• Usage while breast-feeding?

  This medicine is not recommended for use in breastfeeding women unless absolutely necessary. Your doctor will determine the best course of treatment after evaluating the potential benefits and risks associated with the use of this medicine.

• Allergy

  This medicine is not recommended for use in patients with a known allergy to FIBATIDE 2mg|ml Injection 10ml vial or any other inactive ingredients present along with it.

• Bleeding disorder

  This medicine is not recommended for use in patients with a history of bleeding disorders due to blood coagulation issues (bleeding diathesis) or active abnormal bleeding within the previous 30 days due to the increased risk of worsening of the patient’s condition.

• Severe hypertension

  This medicine is not recommended for use in patients suffering from severe hypertension (high blood pressure levels more than 200/110 mm Hg) that is not adequately controlled using appropriate medication due to the increased risk of worsening of the patient’s condition.

• Major surgery

  This medicine is not recommended for use in patients who have undergone major surgery within the preceding 6 weeks due to the increased risk of worsening of the patient’s condition.

• Stroke

  This medicine is not recommended for use in patients with a history of stroke within the past 30 days or any history of hemorrhagic stroke (an emergency condition where blood vessels rupture within the brain) due to the increased risk of worsening of the patient’s condition.

• GP IIb/IIIa inhibitor

  This medicine is not recommended for use in patients receiving or patients about to receive other parenteral GP IIb/IIIa inhibitors since it may worsen the patient's condition.

• Hemodialysis

  This medicine is not recommended for use in patients who are undergoing dialysis or have a dependency on this procedure due to the increased risk of worsening of the patient’s condition.

• Pregnancy

  This medicine is not recommended for use in pregnant women unless absolutely necessary. Your doctor will determine the best course of treatment after evaluating the potential benefits and risks associated with the use of this medicine.

• Breast-feeding

  This medicine is not recommended for use in breastfeeding women unless absolutely necessary. Your doctor will determine the best course of treatment after evaluating the potential benefits and risks associated with the use of this medicine.

• Other medicines

  This medicine may interact with many other medicines and may cause severe adverse effects. Hence, it is advised that you inform the doctor about all your current medicines including any herbs and supplements before beginning treatment with this medicine.

• Use in children

  This medicine is not recommended for use in patients less than 18 years of age since the safety and efficacy of use are not clinically established.

• Use in elderly

  This medicine should be used with caution and monitoring in elderly patients since the risk of severe adverse effects is significantly high.

• Bleeding test

  It is recommended to collect blood samples and test the possibility of unexpected bleeding before and during therapy with this medicine. Patients should always be monitored for signs and symptoms that could indicate unusual or unexpected bleeding.

• Kidney diseases

  This medicine should be used with caution in patients with kidney diseases due to the increased risk of severe adverse effects. Regular monitoring of kidney function tests is necessary while receiving this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition.

• Hypertension

  This medicine should be used with caution and monitoring in patients suffering from hypertension (high blood pressure levels). Use is not recommended if the increase in blood pressure level is very high (severe hypertension) and the patient is not receiving appropriate therapy to correct the blood pressure level.

• Surgery

  This medicine is not recommended for use in patients who have undergone major surgery, injury, trauma, or any other medical emergency within the past 6 weeks. Inform your doctor in advance so that the dose regimen with this medicine can be appropriately adjusted.

This medicine is usually administered in the clinical/hospital setting under the supervision of a qualified healthcare professional. The dose strength and method of administration are likely to vary based on multiple criteria. You may be asked to frequently undertake certain tests before and during therapy with this medicine. Inform the doctor if you have a known allergy to this medicine. Report all your current medicines as well as your medical conditions to the doctor before receiving this medicine.

• Usage does not depend on food timings
• To be taken as instructed by doctor
• May cause sleepiness

• drugs.com - Eptifibatide [Internet]. Available from: https://www.drugs.com/integrilin.html [cited 7/9/2020]. 2019
• medicinenet.com - Eptifibatide [Internet]. Available from: https://www.medicinenet.com/eptifibatide-injectable/article.htm#:~:text=Eptifibatide%20works%20by%20preventing%20platelets,heart%20to%20close%20back%20up. [cited 7/9/2020].